Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,323 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TTP-HUS associated with sunitinib.
Choi MK, Hong JY, Jang JH, Lim HY. Choi MK, et al. Among authors: hong jy. Cancer Res Treat. 2008 Dec;40(4):211-3. doi: 10.4143/crt.2008.40.4.211. Epub 2008 Dec 31. Cancer Res Treat. 2008. PMID: 19688133 Free PMC article.
Unique perception of clinical trials by Korean cancer patients.
Lee SJ, Park LC, Lee J, Kim S, Choi MK, Hong JY, Park S, Maeng CH, Chang W, Kim YS, Park SH, Park JO, Lim HY, Kang WK, Park YS. Lee SJ, et al. Among authors: hong jy. BMC Cancer. 2012 Dec 12;12:594. doi: 10.1186/1471-2407-12-594. BMC Cancer. 2012. PMID: 23234342 Free PMC article.
Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.
Lee J, Hong YS, Hong JY, Han SW, Kim TW, Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, Kim KM, Sohn I, Park SH, Park JO, Lim HY, Cho YB, Lee WY, Yun SH, Kim HC, Park YS, Kang WK. Lee J, et al. Among authors: hong jy, hong ys. Invest New Drugs. 2014 Jun;32(3):535-41. doi: 10.1007/s10637-014-0065-x. Epub 2014 Jan 28. Invest New Drugs. 2014. PMID: 24468885 Clinical Trial.
Erratum to: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.
Lee J, Hong YS, Hong JY, Han SW, Kim TW, Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, Kim KM, Sohn I, Park SH, Park JO, Lim HY, Cho YB, Lee WY, Yun SH, Kim HC, Park YS, Kang WK. Lee J, et al. Among authors: hong jy, hong ys. Invest New Drugs. 2015 Feb;33(1):269-70. doi: 10.1007/s10637-014-0162-x. Invest New Drugs. 2015. PMID: 25236593 No abstract available.
Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.
Lee J, Kim HC, Hong JY, Wang K, Kim SY, Jang J, Kim ST, Park JO, Lim HY, Kang WK, Park YS, Lee J, Lee WY, Park YA, Huh JW, Yun SH, Do IG, Kim SH, Balasubramanian S, Stephens PJ, Ross JS, Li GG, Hornby Z, Ali SM, Miller VA, Kim KM, Ou SH. Lee J, et al. Among authors: hong jy. Oncotarget. 2015 Sep 15;6(27):24320-32. doi: 10.18632/oncotarget.4462. Oncotarget. 2015. PMID: 26172300 Free PMC article.
1,323 results